MIJ is pleased to announce its recent participation in the Series A financing round of Cytospire Therapeutics Limited.

Cytospire is developing pan-gamma delta T cell engagers designed to bind and activate both tissue and blood resident gamma delta T cells. This technology opens a path to safer and more efficacious targeting of well-validated antigens that are intractable to conventional T cell engagers.

The round was led by 4BIO Capital, with investment from MIJ, new syndicate members Servier Ventures, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Modi Ventures and Pathway Bioventures, as well as from existing investors Abingworth and LifeArk Ventures.

Its lead program, CYT X300 targeting EGFR-positive solid tumors, is currently being advanced through IND-enabling studies.